AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Alopecia universalis treatment 201510/10/2023 ![]() In patients with AA, hair follicles in the growing phase prematurely enter the non-proliferative involution and resting phases, causing hair loss and growth inhibition. Finally, AA universalis, when there is total loss of hair on the entire body, face and scalp. AA totalis, which presents with complete loss of scalp hair. There are three types of AA: AA patchy, characterized by appearance of round and oval patches on the head or on other places of the body. 2,3 AA can appear in any age range and does not distinguish between sexes. 1 A worldwide prevalence of 1 per 1,000 people is estimated, with a lifetime risk of approximately 2%. Palabras clave: Alopecia, tofacitinib, baricitinib, evaluación, eficaciaĪlopecia areata (AA) is an autoimmune disease that occurs with a chronic, recurrent inflammatory process that weakens the hair follicles, causing hair loss, especially on the scalp. Los efectos adversos encontrados son los esperados de esta clase de fármacos. Según los resultados obtenidos en los estudios y revisiones publicadas, los inhibidores de la JAK-quinasa parecen inducir el crecimiento del cabello en aproximadamente la mitad de los pacientes según la abundante evidencia disponible sobre tofacitinib. En nuestra revisión se incluyeron 2 ECA (estudios pivotales de baricitinib), 1 metanálisis en red, 3 revisiones sistemáticas/metanálisis y 2 estudios comparativos abiertos. Realizamos una búsqueda electrónica y un estudio de serie de casos que analizó la efectividad del uso off-label de tofacitinib en alopecia areata en nuestros pacientes. Se ha demostrado que los inhibidores de la cinasa de Janus (JAK) son efectivos por vía oral en pacientes con AA moderada a grave. La alopecia areata (AA) es una enfermedad autoinmune que cursa con un proceso inflamatorio crónico y recurrente que debilita los folículos pilosos, provocando la caída del cabello. Keywords: Alopecia, tofacitinib, baricitinib, evaluación, eficacia Evidencia del uso off-label de tofacitinib en alopecia areata The adverse effects founded are those expected from this class of drugs. According to the results obtained in the studies and published reviews, JAK-kinase inhibitors appear to induce hair regrowth in about half of patients, specially according to the abundant tofacitinib available evidence. 2 RCTs were included in our review (baricitinib pivotal studies), 1 network meta-analysis, 3 systematic review/metanalysis and 2 open comparative studies. We performed an electronic search and a case series study analysing effectiveness of tofacitinib off-label use in alopecia areata in our patients. Janus kinase (JAK) inhibitors have been shown to be effective orally in patients with moderate-severe AA. ![]()
0 Comments
Read More
Leave a Reply. |